ProPhase Labs Secures New Patent for Cancer Risk Assessment Innovation

Author: Evelyn Baker Updated: 08-12-2025 08:13 AM

ProPhase Labs Secures Patent for Esophageal Cancer Risk Detection

ProPhase Labs, Inc. has achieved a significant milestone with the issuance of U.S. Patent No. 12379378-B2. This patent focuses on innovative biomarker-driven systems and methods designed to assess the risk progression in Barrett’s esophagus and esophageal adenocarcinoma. Following the validation of the BE-Smart™ test, which boasts an impressive technical success rate exceeding 95%, this patent solidifies ProPhase's commitment to early detection of esophageal diseases.

The Importance of BE-Smart™

The BE-Smart™ molecular diagnostic tool is pivotal in identifying risks associated with esophageal disorders. It has showcased exceptional versatility by effectively working with both brush and forceps biopsies. By leveraging these techniques, BE-Smart™ captures a wider range of epithelial cell types, making it a comprehensive tool for clinicians aiming to detect issues early and improve patient outcomes.

Understanding the Patent's Provisions

U.S. Patent No. 12379378-B2 was filed on December 7, 2023, by its inventors, Joe Abdo, Sumeet K. Mittal, and Devendra K. Agrawal. This patent encompasses methods that enable healthcare professionals to evaluate the risk of Barrett's esophagus and esophageal adenocarcinoma by detecting critical biomarkers such as ISG15, LTF, and others.

Scientific Significance of the Discoveries

The implications of this scientific breakthrough are far-reaching. The patented methods not only play a crucial role in risk analysis but also pave the way for novel treatment approaches. These may include methods for inhibiting cancer cell growth and enhancing the effectiveness of traditional therapies, ultimately aiding in better patient management.

ProPhase Labs' Vision for the Future

“This remarkable achievement, following the validation of BE-Smart™, reinforces our leadership in medical innovation. It brings us closer to transforming early detection and treatment strategies for esophageal conditions,” stated Ted Karkus, the Chief Executive Officer of ProPhase Labs. With the newly issued patent, the company aims to accelerate the commercialization of BE-Smart™, making it accessible to a broader range of patients and healthcare facilities.

Company Overview

ProPhase Labs, Inc. stands at the forefront of the biotechnology and diagnostics industries. Its mission is to create a healthier world through pioneering innovations. The company is known for its Whole Genome Sequencing solutions and the development of groundbreaking diagnostic tools like BE-Smart™, aimed at early cancer detection. With a direct-to-consumer model for health supplements, ProPhase is uniquely positioned for sustainable growth in the health tech sector.

Frequently Asked Questions

What is the significance of the newly issued patent for ProPhase Labs?

The patent protects ProPhase's innovative methods for assessing risks associated with esophageal diseases, enhancing early detection capabilities.

How does BE-Smart™ contribute to cancer diagnosis?

BE-Smart™ demonstrates high technical success in detecting biomarkers from various biopsy techniques, improving early diagnostic accuracy.

What are the key biomarkers identified in the patent?

The patent covers biomarkers such as ISG15, LTF, CNDP2, and others crucial for assessing Barrett's esophagus and cancer risk.

Who are the inventors of the patented technology?

The patent was developed by Joe Abdo, Sumeet K. Mittal, and Devendra K. Agrawal, showcasing expertise in the field.

What is ProPhase's long-term vision?

ProPhase Labs aims to enhance healthcare through innovative solutions and broaden access to their diagnostic tools, shaping future medical practices.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.